Stock XOMA XOMA CORPORATION
Add to a list
To use this feature you must be a member
Log inSign up

Company XOMA Corporation

Equities

XOMA

US98419J2069

Biotechnology & Medical Research

Market Closed - Nasdaq
Other stock markets
 04:00:00 2024-04-25 pm EDT 		5-day change 1st Jan Change
25.36 USD -1.09% Intraday chart for XOMA Corporation +3.13% +37.08%
Apr. 03 XOMA Corporation completed the acquisition of Kinnate Biopharma Inc.. CI
Mar. 08 XOMA Corporation Reports Earnings Results for the Full Year Ended December 31, 2023 CI

Business Summary

XOMA Corporation is a biotechnology royalty aggregator. The Company’s royalty aggregator business is primarily focused on early to mid-stage clinical assets, primarily in Phase I and II, with significant commercial sales potential that are licensed to larger pharmaceutical partners. The Company has a portfolio of economic rights and royalty payments associated with partnered commercial and pre-commercial therapeutic candidates. Its royalty portfolio includes DAY101 (tovorafenib), JNJ-63723283 (cetrelimab), RZ358, arimoclomol, TAK-079 (mezagitamab), BAY-1213790 (osocimab), AFM13 (acimtamig), AB023 (gruticibart), AB002 (E-WE thrombin), AB054, AV-299 (ficlatuzumab), COM902, vosaroxin, aldoxorubicin, INCAGN2385, INCAGN02390, MNPR-101, PBF-680, PBF-677, PBF-999, PBF-1129, PBF-1650, G03-52-01, RZ402, DSUVIA (sufentanil sublingual tablet), IXINITY [coagulation factor IX (recombinant)], VABYSMO (faricimab-svoa), CMP-001 (vidutolimod), and CFZ533 (iscalimab).

Number of employees: 13

Sales per Business

USD in Million2022Weight2023Weight Delta
Pharmaceutical
100.0 %
6 100.0 % 5 100.0 % -21.06%

Sales per region

USD in Million2022Weight2023Weight Delta
United States
76.9 %
4 74.3 % 4 76.9 % -18.29%
Asia Pacific
23.1 %
2 25.7 % 1 23.1 % -29.03%

Managers

Managers TitleAgeSince
Owen Hughes CEO
 Chief Executive Officer 49 22-12-31
Thomas Burns DFI
 Director of Finance/CFO 50 06-08-13
Bradley Sitko CIO
 Chief Investment Officer 43 23-01-02
Juliane Snowden IRC
 Investor Relations Contact - -

Members of the board

Members of the board TitleAgeSince
Heather Franklin BRD
 Director/Board Member 58 21-08-05
Jack Wyszomierski CHM
 Chairman 68 10-08-25
Joseph Limber BRD
 Director/Board Member 71 12-12-11
Matthew Perry BRD
 Director/Board Member 51 17-02-15
Barbara Kosacz BRD
 Director/Board Member 66 18-12-31
Owen Hughes CEO
 Chief Executive Officer 49 22-12-31
Natasha Hernday BRD
 Director/Board Member 52 20-06-29

Share class

VoteQuantityFree-FloatCompany-owned sharesTotal Float
Stock A 0 984,000 0 0 99.58 %
Stock B 1 11,635,015 11,587,438 ( 99.59 %) 0
Stock C 0 1,600 0 0

Shareholders

NameEquities%Valuation
BVF, Inc.
31.26 %
3,633,743 31.26 % 87 M $
Fidelity Management & Research Co. LLC
9.935 %
1,155,033 9.935 % 28 M $
BlackRock Advisors LLC
4.038 %
469,484 4.038 % 11 M $
Vanguard Fiduciary Trust Co.
3.625 %
421,474 3.625 % 10 M $
Opaleye Management, Inc.
2.150 %
250,000 2.150 % 6 M $
Stonepine Capital Management LLC
2.150 %
250,000 2.150 % 6 M $
Geode Capital Management LLC
1.384 %
160,936 1.384 % 4 M $
Acuitas Investments LLC
1.180 %
137,132 1.180 % 3 M $
STATE STREET CORPORATION
1.070 %
124,423 1.070 % 3 M $
TLS Advisors LLC
1.036 %
120,465 1.036 % 3 M $
NameEquities%Valuation
Owen Hughes
0.1250 %
2,000 0.1250 % 50 900 $
Bradley Sitko
0.1250 %
2,000 0.1250 % 50 900 $
NameEquities%Valuation
BVF Partners LP
100.00 %
5,003 100.00 % 120 322 $
NameEquities%Valuation
BVF Partners LP
20.33 %
200,000 20.33 % 5 M $

Company contact information

XOMA Corp.

2200 Powell Street Suite 310

94608, Emeryville

+510 204 7200

http://www.xoma.com
address XOMA Corporation(XOMA)

Sector

Healthcare
Pharmaceuticals & Medical Research
Biotechnology & Medical Research
Biotechnology & Medical Research
Bio Therapeutic Drugs

Sales per region

Ratings for XOMA Corporation

Trading Rating
Investor Rating
ESG Refinitiv
C-
More Ratings

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
2
Last Close Price
25.64 USD
Average target price
74 USD
Spread / Average Target
+188.61%
Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Bio Therapeutic Drugs

1st Jan change Capi.
XOMA CORPORATION Stock XOMA Corporation
+37.08% 298M
VERTEX PHARMACEUTICALS INCORPORATED Stock Vertex Pharmaceuticals Incorporated
-2.26% 104B
REGENERON PHARMACEUTICALS, INC. Stock Regeneron Pharmaceuticals, Inc.
+1.41% 97.42B
ARGENX SE Stock argenx SE
+0.79% 22.2B
BIONTECH SE Stock BioNTech SE
-17.84% 21.23B
GENMAB A/S Stock Genmab A/S
-11.11% 18.33B
WUXI APPTEC CO., LTD. Stock WuXi AppTec Co., Ltd.
-42.83% 16.35B
BEIGENE, LTD. Stock BeiGene, Ltd.
-17.63% 15.06B
NEUROCRINE BIOSCIENCES, INC. Stock Neurocrine Biosciences, Inc.
+4.55% 13.98B
SAREPTA THERAPEUTICS, INC. Stock Sarepta Therapeutics, Inc.
+32.11% 11.66B
Bio Therapeutic Drugs
  1. Stock Market
  2. Equities
  3. XOMA Stock
  4. Company XOMA Corporation